<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/2079-701X-2020-2-55-66</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-5522</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>НЕЙРОДЕГЕНЕРАТИВНЫЕ ЗАБОЛЕВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>NEURODEGENERATIVE DISEASES</subject></subj-group></article-categories><title-group><article-title>Гетерогенность речевых нарушений при болезни Паркинсона: возможности классификации, диагностики и терапии</article-title><trans-title-group xml:lang="en"><trans-title>Heterogeneity of speech disorders in Parkinson’s disease: potential for classification, diagnostics and therapy</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2600-0573</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Васенина</surname><given-names>Е. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Vasenina</surname><given-names>E. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Васенина Елена Евгеньевна, кандидат медицинских наук, доцент, кафедра неврологии</p><p>125993, Москва, ул. Баррикадная, д. 2/1, стр. 1</p></bio><bio xml:lang="en"><p>Elena E. Vasenina, Cand. of Sci. (Med), Associate Professor, Department of Neurology</p><p>2/1, b. 1, Barrikadnaya St., Moscow, 125993, Russia</p></bio><email xlink:type="simple">hel_vas@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3872-5923</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Левин</surname><given-names>О. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Levin</surname><given-names>O. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Левин Олег Семенович, доктор медицинских наук, профессор, заведующий кафедрой неврологии</p><p>125993, Москва, ул. Баррикадная, д. 2/1, стр. 1</p></bio><bio xml:lang="en"><p>Oleg S. Levin, Dr. of Sci. (Med), Proffesor, Head of the Department of Neurology</p><p>2/1, b. 1, Barrikadnaya St., Moscow, 125993, Russia</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Российская медицинская академия непрерывного профессионального образования</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Russian Medical Academy of Continuous Professional Education</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>03</day><month>03</month><year>2020</year></pub-date><volume>0</volume><issue>2</issue><fpage>55</fpage><lpage>66</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Васенина Е.Е., Левин О.С., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Васенина Е.Е., Левин О.С.</copyright-holder><copyright-holder xml:lang="en">Vasenina E.E., Levin O.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/5522">https://www.med-sovet.pro/jour/article/view/5522</self-uri><abstract><sec><title>Введение</title><p>Введение. Нарушение речи при болезни Паркинсона (БП) является очень распространенным клиническим симптомом. К настоящему моменту структура речевых расстройств до конца не понятна, не существует единых подходов к классификации, не изучен эффект терапии.</p></sec><sec><title>Цель исследования</title><p>Цель исследования: изучение и классификация возможных нарушений речи при БП, изучение взаимосвязи речевых расстройств с моторными и немоторными симптомами, а также поиск оптимальных терапевтических стратегий.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. В исследование первично было включено 324 пациента с БП, из которых на основании тестирования было отобрано 77 пациентов (22,4%) с клинически значимым нарушением речи. Всем пациентам проводилась оценка двигательных нарушений (UPDRS-3), когнитивных нарушений при помощи Адденбрукской когнитивной шкалы, а также оценка аффективных нарушений.</p></sec><sec><title>Результаты</title><p>Результаты. Методом кластерного анализа было выделено 4 подтипа речевых расстройств, которые были обозначены как дисфазия (адинамическая, диспросодическая, конструктивная и логопеническая). Ни одна из выделенных форм не была связана с тяжестью паркинсонизма и общей выраженностью когнитивного снижения, что позволило рассматривать дисфазию как отдельный клинический синдром. Диспросодическая дисфазия отличалась выраженностью аксиальных симптомов (F value = 3,279, p&lt;0,05), адинамическая была связана с более выраженной апатией (F value = 4,2, p &lt; 0,01), конструктивная – с нарушением зрительно-пространственных функций (F value 29,93, p &lt; 0,0001), а логопеническая – с более грубым дефицитом внимания.</p></sec><sec><title>Заключение</title><p>Заключение. Речевые нарушения при БП гетерогенны и могут быть расценены как проявления дисфазии. Выделение различных ее подтипов позволит оптимизировать лечение пациентов с БП.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. Speech disorders in Parkinson’s disease are a very common clinical sign. The structure of speech disorders is at the moment not fully understood, there is no unified approach to classification, therapy effects have not been studied.</p></sec><sec><title>Materials and methods</title><p>Materials and methods: 324 PD patients were primarily included in the study, and from those the patients showing clinically significant speech disorders (22,4%) were selected. All the patients were assessed for motor disorders (UPDRS part 3), cognitive disorders (Addenbrooke’s cognitive examination), as well as affective disorders.</p></sec><sec><title>Results</title><p>Results: by means of cluster analysis we identified 4 subtypes of speech disorders as dysphasia (adynamic, disprosodic, constructive, and logopenic). None of the forms was associated with parkinsonism severity and general severity of cognitive impairment, which allowed to consider dysphasia as a separate clinical syndrome. Disprosodic dysphasia differentiated by severity of axial symptoms (F value = 3.279, p &lt; 0,05), adynamic dysphasia was associated with more pronounced apathy (F value = 4,2, p &lt; 0,01), constructive dysphasia – with impairment of visual-spatial functioning (F value 29,93, p&lt;0,0001), while logopenic dysphasia was associated with more severe attention deficiency.</p></sec><sec><title>Conclusion</title><p>Conclusion: Speech disorders in PD are heterogeneous and can be regarded as manifestations of dysphasia. Identification of various subtypes will allow for optimizing the treatment of PD patients.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>болезнь Паркинсона</kwd><kwd>дисфазия</kwd><kwd>речь</kwd><kwd>аксиальные симптомы</kwd><kwd>апатия</kwd><kwd>зрительно-пространственные функции</kwd><kwd>антидепрессанты</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Parkinson’s disease</kwd><kwd>dysphasia</kwd><kwd>speech</kwd><kwd>axial</kwd><kwd>apathy</kwd><kwd>visual-spatial</kwd><kwd>antidepressant</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Арефьева А.П., Скрипкина Н.А., Васенина Е.Е. Речевые нарушения при болезни Паркинсона. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2019;119(9):32–36. doi: 10.17116/jnevro201911909232.</mixed-citation><mixed-citation xml:lang="en">Arefyeva A.P., Skripkina N.A., Vasenina E.E. Speech disorders in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2019;119(9):32–36. (In Russ.) doi: 10.17116/jnevro201911909232.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Dashtipour K., Tafreshi A., Lee J., Crawley B. Speech disorders in Parkinson’s disease: pathophysiology, medical management and surgical approaches. Neurodegenerative Disease Management. 2018;8(5):337–348. doi: 10.2217/nmt-2018-0021.</mixed-citation><mixed-citation xml:lang="en">Dashtipour K., Tafreshi A., Lee J., Crawley B. Speech disorders in Parkinson’s disease: pathophysiology, medical management and surgical approaches. Neurodegenerative Disease Management. 2018;8(5):337–348. doi: 10.2217/nmt-2018-0021.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Sapir S. Multiple factors are involved in the dysarthria associated with Parkinson’s disease: a review with implications for clinical practice and research. Journal of Speech, Language and Hearing Research. 2014;57(4):1330–1343. doi: 10.1044/2014_jslhr-s-13-0039.</mixed-citation><mixed-citation xml:lang="en">Sapir S. Multiple factors are involved in the dysarthria associated with Parkinson’s disease: a review with implications for clinical practice and research. Journal of Speech, Language and Hearing Research. 2014;57(4):1330–1343. doi: 10.1044/2014_jslhr-s-13-0039.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Rusz J., Cmejla R., Ruzickova H., Ruzicka E. Quantitative acoustic measurements for characterization of speech and voice disorders in early untreated Parkinson’s disease. The Journal of the Acoustical Society of America. 2011;129(1):350–367. doi: 10.1121/1.3514381.</mixed-citation><mixed-citation xml:lang="en">Rusz J., Cmejla R., Ruzickova H., Ruzicka E. Quantitative acoustic measurements for characterization of speech and voice disorders in early untreated Parkinson’s disease. The Journal of the Acoustical Society of America. 2011;129(1):350–367. doi: 10.1121/1.3514381.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Rusz J., Tykalová T., Klempíř J. et al. Effects of dopaminergic replacement therapy on motor speech disorders in Parkinson’s disease: longitudinal follow-up study on previously untreated patients. J Neural Transm. 2016;123:379– 387. doi: 10.1007/s00702-016-1515-8.</mixed-citation><mixed-citation xml:lang="en">Rusz J., Tykalová T., Klempíř J. et al. Effects of dopaminergic replacement therapy on motor speech disorders in Parkinson’s disease: longitudinal follow-up study on previously untreated patients. J Neural Transm. 2016;123:379– 387. doi: 10.1007/s00702-016-1515-8.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Wolfe V.I., Garvin J.S., Bacon M., Waldrop W. Speech changes in Parkinson’s disease during treatment with L-DOPA. Journal of Communication Disorders. 1975;8(3):271–279. doi: 10.1016/0021-9924(75)90019-2.</mixed-citation><mixed-citation xml:lang="en">Wolfe V.I., Garvin J.S., Bacon M., Waldrop W. Speech changes in Parkinson’s disease during treatment with L-DOPA. Journal of Communication Disorders. 1975;8(3):271–279. doi: 10.1016/0021-9924(75)90019-2.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Fabbri M., Guimarães I., Cardoso R. et al. Speech and Voice Response to a Levodopa Challenge in Late-Stage Parkinson’s Disease. Frontiers in neurology. 2017;8:432. doi: 10.3389/fneur.2017.00432.</mixed-citation><mixed-citation xml:lang="en">Fabbri M., Guimarães I., Cardoso R. et al. Speech and Voice Response to a Levodopa Challenge in Late-Stage Parkinson’s Disease. Frontiers in neurology. 2017;8:432. https://doi.org/10.3389/fneur.2017.00432.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Tykalová T., Rusz J., Čmejla R. et al. Effect of dopaminergic medication on speech dysfluency in Parkinson’s disease: a longitudinal study. J Neural Transm. 2015;122:1135–1142. doi: 10.1007/s00702-015-1363-y.</mixed-citation><mixed-citation xml:lang="en">Tykalová T., Rusz J., Čmejla R. et al. Effect of dopaminergic medication on speech dysfluency in Parkinson’s disease: a longitudinal study. J Neural Transm. 2015;122:1135–1142. doi: 10.1007/s00702-015-1363-y.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Herrera E., Cuetos F., Ribacoba R. Verbal fluency in Parkinson’s disease patients on/off dopamine medication. Neuropsychologia. 2012;50(14):3636–3640. doi: 10.1016/j.neuropsychologia.2012.09.016.</mixed-citation><mixed-citation xml:lang="en">Herrera E., Cuetos F., Ribacoba R. Verbal fluency in Parkinson’s disease patients on/off dopamine medication. Neuropsychologia. 2012;50(14):3636–3640. doi: 10.1016/j.neuropsychologia.2012.09.016.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Magdalinou N.K., Golden H.L., Nicholas J.M., Witoonpanich P. et al. Verbal adynamia in parkinsonian syndromes: behavioral correlates and neuroanatomical substrate. Neurocase. 2018;24(4):204–212. doi: 10.1080/13554794.2018.1527368.</mixed-citation><mixed-citation xml:lang="en">Magdalinou N.K., Golden H.L., Nicholas J.M., Witoonpanich P. et al. Verbal adynamia in parkinsonian syndromes: behavioral correlates and neuroanatomical substrate. Neurocase. 2018;24(4):204–212. doi: 10.1080/13554794.2018.1527368.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Johari K., Walenski M., Reifegerste J. et al. A dissociation between syntactic and lexical processing in Parkinson’s disease. J Neurolinguistics. 2019;51:221–235. doi: 10.1016/j.jneuroling.2019.03.004.</mixed-citation><mixed-citation xml:lang="en">Johari K., Walenski M., Reifegerste J. et al. A dissociation between syntactic and lexical processing in Parkinson’s disease. J Neurolinguistics. 2019;51:221–235. doi: 10.1016/j.jneuroling.2019.03.004.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Chen Y.-W., Watson P.J. Speech production and sensory impairment in mild Parkinson’s disease. J Acoust Soc Am. 2017;141(5):3030–3041. doi: 10.1121/1.4980138.</mixed-citation><mixed-citation xml:lang="en">Chen Y.-W., Watson P.J. Speech production and sensory impairment in mild Parkinson’s disease. J Acoust Soc Am. 2017;141(5):3030–3041. doi: 10.1121/1.4980138.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Friedman J.H. Misperceptions and Parkinson’s disease. Journal of the Neurological Sciences. 2017;374:42–46. doi: 10.1016/j.jns.2016.12.059.</mixed-citation><mixed-citation xml:lang="en">Friedman J.H. Misperceptions and Parkinson’s disease. Journal of the Neurological Sciences. 2017;374:42–46. doi: 10.1016/j.jns.2016.12.059.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Postuma R.B., Berg D., Stern M. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591–1601. doi: 10.1002/mds.26424.</mixed-citation><mixed-citation xml:lang="en">Postuma R.B., Berg D., Stern M. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591–1601. doi: 10.1002/mds.26424.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Fong M.W.M., Van Patten R., Fucetola R.P. The Factor Structure of the Boston Diagnostic Aphasia Examination, Third Edition. J Int Neuropsychol Soc. 2019;25(7):772–776. doi: 10.1017/S1355617719000237.</mixed-citation><mixed-citation xml:lang="en">Fong M.W.M., Van Patten R., Fucetola R.P. The Factor Structure of the Boston Diagnostic Aphasia Examination, Third Edition. J Int Neuropsychol Soc. 2019;25(7):772–776. doi: 10.1017/S1355617719000237.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Mioshi E., Dawson K., Mitchell J., Arnold R., Hodges J.R. The Addenbrooke’s Cognitive Examination Revised (ACE‐R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry. 2006;21(11):1078–1085. doi: 10.1002/gps.1610.</mixed-citation><mixed-citation xml:lang="en">Mioshi E., Dawson K., Mitchell J., Arnold R., Hodges J.R. The Addenbrooke’s Cognitive Examination Revised (ACE‐R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry. 2006;21(11):1078–1085. doi: 10.1002/gps.1610.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Левин О.С., Лавров А.Ю., Ляшенко Е.А., Васенина Е.Е., Трусова Н.А., Датиева В.К., Макотрова Т.А., Пилипенко А.Ю. Валидизация русскоязычной версии модифицированной Адденбрукской когнитивной шкалы для диагностики болезни Альцгеймера. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2015;115(6):36–39. doi: 10.17116/jnevro20151156236-39.</mixed-citation><mixed-citation xml:lang="en">Levin O.S., Lavrov A.Y., Lyashenko Е.А., Vasenina E.E., Trusova N.A., Datieva V.K., Makotrova T.A., Pilipenko A.Y. Validation of the Russian version of the modified Addenbrooke’s cognitive examination for Alzheimer’s disease diagnosis. Korsakov Journal of Neurology and Psychiatry = Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2015;115(6):36–39. (In Russ.) doi: 10.17116/jnevro20151156236-39.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Fahn S., Elton R.L. UPDRS program members Parkinson’s Disease Rating Scale. In: Fahn S., Marsden C.D., Goldstein M., Calne D.B. (eds.). Recent developments in Parkinson’s disease. Macmillanm Healthcare Information, Florham Park; 1987. Vol. 2, pp. 153–163.</mixed-citation><mixed-citation xml:lang="en">Fahn S., Elton R.L. UPDRS program members Parkinson’s Disease Rating Scale. In: Fahn S., Marsden C.D., Goldstein M., Calne D.B. (eds.). Recent developments in Parkinson’s disease. Macmillanm Healthcare Information, Florham Park; 1987. Vol. 2, pp. 153–163.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Zigmond A.S., Snaith R.P. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67(6):361–370. doi: 10.1111/j.1600-0447.1983.tb09716.x.</mixed-citation><mixed-citation xml:lang="en">Zigmond A.S., Snaith R.P. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67(6):361–370. doi: 10.1111/j.1600-0447.1983.tb09716.x.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Starkstein S. Apathy in Parkinson’s disease: Diagnostic and etiological dilemmas. Mov Disord. 2012;27(2):174–178. doi: 10.1002/mds.24061.</mixed-citation><mixed-citation xml:lang="en">Starkstein S. Apathy in Parkinson’s disease: Diagnostic and etiological dilemmas. Mov Disord. 2012;27(2):174–178. doi: 10.1002/mds.24061.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Mesulam M.‐M. Primary progressive aphasia. Ann Neurol. 2001;49(4):425–432. Available at: https://www.ncbi.nlm.nih.gov/pubmed/11310619.</mixed-citation><mixed-citation xml:lang="en">Mesulam M.‐M. Primary progressive aphasia. Ann Neurol. 2001;49(4):425–432. Available at: https://www.ncbi.nlm.nih.gov/pubmed/11310619.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Gorno-Tempini M.L., Hillis A.E., Weintraub S. et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006–1014. doi: 10.1212/WNL.0b013e31821103e6.</mixed-citation><mixed-citation xml:lang="en">Gorno-Tempini M.L., Hillis A.E., Weintraub S. et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006– 1014. doi: 10.1212/WNL.0b013e31821103e6.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Васенина Е.Е., Левин О.С. Первичные прогрессирующие афазии. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2014;114(6):3-12. Режим доступа: https://www.mediasphera.ru/issues/zhurnal-nevrologii-ipsikhiatrii-im-s-s-korsakova-2/2014/6/031997-72982014620/annotation.</mixed-citation><mixed-citation xml:lang="en">Vasenina E.E., Levin O.S. Primary progressive aphasias. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2014;114(6):3-12. (In Russ.) Available at: https://www.mediasphera. ru/issues/zhurnal-nevrologii-i-psikhiatrii-im-ss-korsakova-2/2014/6/031997-72982014620/annotation.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Botha H., Josephs K.A. Primary Progressive Aphasias and Apraxia of Speech. Continuum (Minneap Minn). 2019;25(1):101–127. doi: 10.1212/CON.0000000000000699.</mixed-citation><mixed-citation xml:lang="en">Botha H., Josephs K.A. Primary Progressive Aphasias and Apraxia of Speech. Continuum (Minneap Minn). 2019;25(1):101–127. doi: 10.1212/CON.0000000000000699.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Utianski R.L., Duffy J.R., Clark H.M. et al. Prosodic and phonetic subtypes of primary progressive apraxia of speech. Brain Lang. 2018;184:54–65. doi: 10.1016/j.bandl.2018.06.004.</mixed-citation><mixed-citation xml:lang="en">Utianski R.L., Duffy J.R., Clark H.M. et al. Prosodic and phonetic subtypes of primary progressive apraxia of speech. Brain Lang. 2018;184:54–65. doi: 10.1016/j. bandl.2018.06.004.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Kotagal V. Is PIGD a legitimate motor subtype in Parkinson disease? Annals of clinical and translational neurology. 2016;3(6):473–477. doi: 10.1002/acn3.312.</mixed-citation><mixed-citation xml:lang="en">Kotagal V. Is PIGD a legitimate motor subtype in Parkinson disease? Annals of clinical and translational neurology. 2016;3(6):473–477. doi: 10.1002/acn3.312.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Лурия А.Р. О патологии грамматических операций. В: Смирнов А.А. (ред.). Известия АПН РСФСР. Выпуск 3: Вопросы педагогической психологии. М.; Л.: Изд-во Акад. пед. наук РСФСР; 1946. С. 61–98. Режим доступа: http://elib.gnpbu.ru/text/izvestiya-apn_vyp3_1946/go,2;fs,0/.</mixed-citation><mixed-citation xml:lang="en">Luria A.R. On the pathology of grammatical operations. In the book: Smirnov A.A. (ed.). Izvestiya APN RSFSR. Issue 3: Issues of pedagogical psychology. Moscow; Leningrad: Publishing house of the Academy of Sciences of the RSFSR; 1946. pp. 61–98. (In Russ.) Available at: http://elib.gnpbu.ru/text/izvestiya-apn_vyp3_1946/go,2;fs,0/.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Leyton C.E., Hodges J.R. Towards a Clearer Definition of Logopenic Progressive Aphasia. Curr Neurol Neurosci Rep. 2013;13(11):396. doi: 10.1007/s11910-013-0396-6.</mixed-citation><mixed-citation xml:lang="en">Leyton C.E., Hodges J.R. Towards a Clearer Definition of Logopenic Progressive Aphasia. Curr Neurol Neurosci Rep. 2013;13(11):396. doi: 10.1007/s11910-013-0396-6.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Giannini L., Irwin D.J., McMillan C.T. et al. Clinical marker for Alzheimer disease pathology in logopenic primary progressive aphasia. Neurology. 2017;88(24):2276–2284. doi: 10.1212/WNL.0000000000004034.</mixed-citation><mixed-citation xml:lang="en">Giannini L., Irwin D.J., McMillan C.T. et al. Clinical marker for Alzheimer disease pathology in logopenic primary progressive aphasia. Neurology. 2017;88(24):2276–2284. doi: 10.1212/WNL.0000000000004034.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Mundt J.C., Vogel A.P., Feltner D.E., Lenderking W.R. Vocal acoustic biomarkers of depression severity and treatment response. Biol Psychiatry. 2012;72(7):580–587. doi: 10.1016/j.biopsych.2012.03.015.</mixed-citation><mixed-citation xml:lang="en">Mundt J.C., Vogel A.P., Feltner D.E., Lenderking W.R. Vocal acoustic biomarkers of depression severity and treatment response. Biol Psychiatry. 2012;72(7):580–587. doi: 10.1016/j.biopsych.2012.03.015.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Friess E., Kuempfel T., Modell S. et al. Paroxetine treatment improves motor symptoms in patients with multiple system atrophy. Parkinsonism Relat Disord. 2006;12(7):432–437. doi: 10.1016/j.parkreldis.2006.04.002.</mixed-citation><mixed-citation xml:lang="en">Friess E., Kuempfel T., Modell S. et al. Paroxetine treatment improves motor symptoms in patients with multiple system atrophy. Parkinsonism Relat Disord. 2006;12(7):432–437. doi: 10.1016/j.parkreldis.2006.04.002.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Huang J., Liu X., Luo X. et al. Effects of Fluoxetine on Poststroke Dysphagia: A Clinical Retrospective Study. J Stroke Cerebrovasc Dis. 2018;27(11):3320–3327. doi: 10.1016/j.jstrokecerebrovasdis.2018.07.034.</mixed-citation><mixed-citation xml:lang="en">Huang J., Liu X., Luo X. et al. Effects of Fluoxetine on Poststroke Dysphagia: A Clinical Retrospective Study. J Stroke Cerebrovasc Dis. 2018;27(11):3320–3327. doi: 10.1016/j.jstrokecerebrovasdis.2018.07.034.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Васенина Е.Е., Ганькина О.А. Нейропсихиатрические нарушения при деменции: механизмы развития и подходы к коррекции. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2017;117(6):58–65. doi: 10.17116/jnevro20171176258-65.</mixed-citation><mixed-citation xml:lang="en">Vasenina E.E., Gan’kina O.A. Neuropsychiatric disorders in dementia: mechanisms and treatment approach. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2017;117(6):58–65. (In Russ.) doi: 10.17116/jnevro20171176258-65.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Richard I.H., Mc Dermott M.P., Kurlan R., et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology. 2012;78(16):1229–1236. doi: 10.1212/WNL.0b013e3182516244.</mixed-citation><mixed-citation xml:lang="en">Richard I.H., Mc Dermott M.P., Kurlan R., et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology. 2012;78(16):1229–1236. doi: 10.1212/WNL.0b013e3182516244.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
